In vitro translation to study HIV protease activity

Methods in Molecular Biology

Volumn 375, Issue , 2007, Pages 135-149

  Matsuda, Zene ^a   Iga, Mutsunori ^a   Miyauchi, Kosuke ^a   Komano, Jun ^a   Morishita, Kazuhiro ^a   Okayama, Akihiko ^a   Tsubouchi, Hirohito ^a  

^a NONE

Author keywords

Drug resistance; ELISA; Genotyping; HIV 1; P24; Phenotyping; Protease; Protease inhibitor

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

INTEGRASE INHIBITOR; PROTEINASE;

ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; METHODOLOGY; MOLECULAR BIOLOGY; PROTEIN SYNTHESIS; REVIEW;

DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INTEGRASE INHIBITORS; HIV PROTEASE; HIV-1; MOLECULAR BIOLOGY; PROTEIN BIOSYNTHESIS; TRANSCRIPTION, GENETIC;

EID: 34547653036     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-388-9:135     Document Type: Article

References (20)

1. Besch, C. L. (2004) Antiretroviral therapy in drug-naive patients infected with human immunodeficiency virus. Am. J. Med. Sci. 328, 3-9.
2. Yeni, P. G., Hammer, S. M., Hirsch, M. S., et al. (2004) Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292, 251-265.
3. Meek, T. D., Dayton, B. D., Metcalf, B. W., et al. (1989) Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. Proc. Natl. Acad. Sci. USA 86, 1841-1845.
4. Gottlinger, H. G., Sodroski, J. G., and Haseltine, W. A. (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86, 5781-5785.
5. Johnson, V. A., Brun-Vezinet, F., Clotet, B., et al. (2004) Update of the drug resistance mutations in HIV-1: 2004. Top. HIV Med. 12, 119-124.
6. Kutilek, V. D., Sheeter, D. A., Elder, J. H., and Torbett, B. E. (2003) Is resistance futile? Curr. Drug Targets Infect. Disord. 3, 295-309.
7. Cohen, C. J., Hunt, S., Sension, M., et al. (2002) A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. Aids 16, 579-588.
8. Durant, J., Clevenbergh, P., Halfon, P., et al. (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353, 2195-2199.
9. Zhang, M. and Versalovic, J. (2002) HIV update. Diagnostic tests and markers of disease progression and response to therapy. Am. J. Clin. Pathol. 118, S26-S32.
10. Maldarelli, F. (2003) HIV-1 fitness and replication capacity: what are they and can they help in patient management? Curr. Infect. Dis. Rep. 5, 77-84.
11. Jacks, T., Power, M. D., Masiarz, F. R., Luciw, P. A., Barr, P. J., and Varmus, H. E. (1988) Characterization of ribosomal frameshifting in HIV1 gag-pol expression. Nature 331, 280-283.
12. Zybarth, G. and Carter, C. (1995) Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J. Virol. 69, 3878-3884.
13. Ishima, R., Torchia, D. A., Lynch, S. M., Gronenbom, A. M., and Louis, J. M. (2003) Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. J. Biol. Chem. 278, 43,311-43,319.
14. Rangwala, S. H., Finn, R. F., Smith, C. E., et al. (1992) High-level production of active HIV-1 protease in Escherichia coli. Gene 122, 263-269.
15. Iga, M., Matsuda, Z., Okayama, A., et al. (2002) Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. J. Virol. Methods 106, 25-37.
16. Hashida, S., Hashinaka, K., Nishikata, I., et al. (1996) Ultrasensitive and more specific enzyme immunoassay (immune complex transfer enzyme immunoassay) for p24 antigen of HIV-1 in serum using affinity-purified rabbit anti-p24 Fab' and monoclonal mouse anti-p24 Fab'. J. Clin. Lab. Anal. 10, 302-307.
17. Patick, A. K., Duran, M., Cao, Y., et al. (1998) Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42, 2637-2644.
18. Condra, J. H., Holder, D. J., Schleif, W. A., et al. (1996) Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70, 8270-8276.
19. Clementi, M. (2004) Can modulation of viral fitness represent a target for anti-HIV-1 strategies? New Microbiol. 27, 207-214.
20. Pettit, S. C., Everitt, L. E., Choudhury, S., Dunn, B. M., and Kaplan, A. H. (2004) Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J. Virol. 78, 8477-8485.